A phase Ib/II study of CPI-444 in Combination with Atezolizumab as second-line therapy in patients with non-small cell lung cancer (NSCLC) who are resistant/refractory to prior therapy with an anti-PD(L)-1 antibody

Trial Profile

A phase Ib/II study of CPI-444 in Combination with Atezolizumab as second-line therapy in patients with non-small cell lung cancer (NSCLC) who are resistant/refractory to prior therapy with an anti-PD(L)-1 antibody

Planning
Phase of Trial: Phase I/II

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs CPI 444 (Primary) ; Atezolizumab
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 03 Aug 2017 According to a Corvus Pharmaceuticals media release, this trial is expected to be initiated in the fourth quarter of 2017.
    • 06 May 2017 New trial record
    • 02 May 2017 According to a Corvus Pharmaceuticals media release, patient enrollment in this study is expected to begin in the second half of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top